These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 29205910

  • 1. Role of intravenous immunoglobulin in the treatment of Kawasaki disease.
    Lo MS, Newburger JW.
    Int J Rheum Dis; 2018 Jan; 21(1):64-69. PubMed ID: 29205910
    [Abstract] [Full Text] [Related]

  • 2. Adjunctive therapies in Kawasaki disease.
    Tremoulet AH.
    Int J Rheum Dis; 2018 Jan; 21(1):76-79. PubMed ID: 29076637
    [Abstract] [Full Text] [Related]

  • 3. Role of glucocorticoids in Kawasaki disease.
    Miura M.
    Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
    [Abstract] [Full Text] [Related]

  • 4. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
    Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M.
    Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
    [Abstract] [Full Text] [Related]

  • 5. Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease.
    Takeshita S, Kawamura Y, Nakatani K, Tsujimoto H, Tokutomi T.
    Clin Pediatr (Phila); 2005 Jun; 44(5):423-6. PubMed ID: 15965549
    [Abstract] [Full Text] [Related]

  • 6. The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study.
    Kanai T, Takeshita S, Kawamura Y, Kinoshita K, Nakatani K, Iwashima S, Takizawa Y, Hirono K, Mori K, Yoshida Y, Nonoyama S.
    Heart Vessels; 2020 Oct; 35(10):1463-1472. PubMed ID: 32449049
    [Abstract] [Full Text] [Related]

  • 7. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I, Marino A, Simonini G, Cimaz R.
    Clin Exp Rheumatol; 2012 Oct; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract] [Full Text] [Related]

  • 8. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
    Shiraishi T, Yamamoto T.
    Pediatr Dermatol; 2013 Oct; 30(3):e30-1. PubMed ID: 22304420
    [Abstract] [Full Text] [Related]

  • 9. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
    Amarilyo G, Koren Y, Brik Simon D, Bar-Meir M, Bahat H, Helou MH, Mendelson A, Hezkelo N, Chodick G, Berkun Y, Eisenstein E, Butbul Aviel Y, Barkai G, Bolkier Y, Padeh S, Brik R, Hashkes PJ, Harel L, Uziel Y.
    Clin Exp Rheumatol; 2017 Oct; 35 Suppl 103(1):209-212. PubMed ID: 28079513
    [Abstract] [Full Text] [Related]

  • 10. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

  • 11. Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population.
    Sánchez-Manubens J, Antón J, Bou R, Iglesias E, Calzada-Hernandez J, Borlan S, Gimenez-Roca C, Rivera J, Kawasaki Disease in Catalonia Working Group.
    Rheumatol Int; 2016 Jul 06; 36(7):905-10. PubMed ID: 27215220
    [Abstract] [Full Text] [Related]

  • 12. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 13. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
    Luban NL, Wong EC, Henrich Lobo R, Pary P, Duke S.
    Transfusion; 2015 Jul 15; 55 Suppl 2():S90-4. PubMed ID: 26174904
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
    Fukui S, Seki M, Minami T, Kotani K, Oka K, Yokomizo A, Matsubara D, Sato T, Nozaki Y, Saito M, Kikuchi Y, Miyamoto K, Monden Y, Yamagata T.
    Pediatr Rheumatol Online J; 2021 Jul 03; 19(1):107. PubMed ID: 34217297
    [Abstract] [Full Text] [Related]

  • 15. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
    Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
    J Pediatr; 2022 Jan 03; 240():158-163.e4. PubMed ID: 34461064
    [Abstract] [Full Text] [Related]

  • 16. Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease.
    Oda T, Nagata H, Nakashima Y, Nanishi E, Takada Y, Nishimura M, Kubo E, Hatae K, Ohga S.
    J Pediatr; 2019 Nov 03; 214():227-230. PubMed ID: 31351682
    [Abstract] [Full Text] [Related]

  • 17. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q.
    BMC Pediatr; 2019 May 17; 19(1):158. PubMed ID: 31101091
    [Abstract] [Full Text] [Related]

  • 18. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
    Jibiki T, Kato I, Shiohama T, Abe K, Anzai S, Takeda N, Yamaguchi KI, Kanazawa M, Kurosaki T.
    Pediatr Int; 2011 Oct 17; 53(5):729-735. PubMed ID: 21342358
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance.
    Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, Atz AM, Printz BF, Baker A, Vetter VL, Newburger JW, Pediatric Heart Network Investigators.
    J Pediatr; 2011 May 17; 158(5):831-835.e3. PubMed ID: 21168857
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ, Jung JW.
    Yonsei Med J; 2014 Sep 17; 55(5):1260-6. PubMed ID: 25048483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.